Annual EBIT
-$235.89 M
-$106.50 M-82.31%
December 31, 2023
Summary
- As of February 20, 2025, VRDN annual earnings before interest & taxes is -$235.89 million, with the most recent change of -$106.50 million (-82.31%) on December 31, 2023.
- During the last 3 years, VRDN annual EBIT has fallen by -$125.68 million (-114.04%).
- VRDN annual EBIT is now -119639.59% below its all-time high of -$197.00 thousand, reached on December 31, 2013.
Performance
VRDN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$75.69 M
-$11.29 M-17.53%
September 30, 2024
Summary
- As of February 20, 2025, VRDN quarterly earnings before interest & taxes is -$75.69 million, with the most recent change of -$11.29 million (-17.53%) on September 30, 2024.
- Over the past year, VRDN quarterly EBIT has dropped by -$28.63 million (-60.83%).
- VRDN quarterly EBIT is now -29862.09% below its all-time high of $254.30 thousand, reached on December 31, 2013.
Performance
VRDN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$253.98 M
-$28.63 M-12.70%
September 30, 2024
Summary
- As of February 20, 2025, VRDN TTM earnings before interest & taxes is -$253.98 million, with the most recent change of -$28.63 million (-12.70%) on September 30, 2024.
- Over the past year, VRDN TTM EBIT has dropped by -$38.42 million (-17.82%).
- VRDN TTM EBIT is now -320177.43% below its all-time high of -$79.30 thousand, reached on March 31, 2013.
Performance
VRDN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
VRDN EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -82.3% | -60.8% | -17.8% |
| 3 y3 years | -114.0% | -60.8% | -17.8% |
| 5 y5 years | -641.1% | -60.8% | -17.8% |
VRDN EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -197.1% | at low | -194.6% | at low | -219.6% | at low |
| 5 y | 5-year | -474.8% | at low | -1301.3% | +16.4% | -758.2% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +16.4% | <-9999.0% | at low |
Viridian Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$75.69 M(+17.5%) | -$253.98 M(+12.7%) |
| Jun 2024 | - | -$64.40 M(+34.3%) | -$225.35 M(+4.4%) |
| Mar 2024 | - | -$47.95 M(-27.3%) | -$215.86 M(-8.5%) |
| Dec 2023 | -$235.89 M(+82.3%) | -$65.94 M(+40.1%) | -$235.89 M(+9.4%) |
| Sep 2023 | - | -$47.06 M(-14.3%) | -$215.56 M(+9.3%) |
| Jun 2023 | - | -$54.90 M(-19.3%) | -$197.24 M(+14.9%) |
| Mar 2023 | - | -$67.99 M(+49.0%) | -$171.68 M(+32.7%) |
| Dec 2022 | -$129.39 M(+62.9%) | -$45.62 M(+58.7%) | -$129.39 M(+14.8%) |
| Sep 2022 | - | -$28.74 M(-2.0%) | -$112.71 M(+15.0%) |
| Jun 2022 | - | -$29.34 M(+14.2%) | -$98.02 M(+13.1%) |
| Mar 2022 | - | -$25.69 M(-11.2%) | -$86.64 M(+9.0%) |
| Dec 2021 | -$79.41 M(-27.9%) | -$28.94 M(+106.1%) | -$79.47 M(-43.7%) |
| Sep 2021 | - | -$14.04 M(-21.8%) | -$141.08 M(+6.5%) |
| Jun 2021 | - | -$17.96 M(-3.0%) | -$132.44 M(+9.6%) |
| Mar 2021 | - | -$18.52 M(-79.6%) | -$120.82 M(+9.6%) |
| Dec 2020 | -$110.21 M(+168.5%) | -$90.56 M(+1576.8%) | -$110.21 M(+272.4%) |
| Sep 2020 | - | -$5.40 M(-14.8%) | -$29.59 M(-16.0%) |
| Jun 2020 | - | -$6.34 M(-19.8%) | -$35.22 M(-6.2%) |
| Mar 2020 | - | -$7.90 M(-20.6%) | -$37.54 M(-8.5%) |
| Dec 2019 | -$41.04 M(+28.9%) | -$9.95 M(-9.8%) | -$41.04 M(-0.3%) |
| Sep 2019 | - | -$11.03 M(+27.2%) | -$41.18 M(+5.7%) |
| Jun 2019 | - | -$8.67 M(-24.0%) | -$38.94 M(+0.4%) |
| Mar 2019 | - | -$11.40 M(+13.0%) | -$38.77 M(+21.8%) |
| Dec 2018 | -$31.83 M | -$10.09 M(+14.8%) | -$31.83 M(+13.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$8.79 M(+3.4%) | -$27.94 M(+12.1%) |
| Jun 2018 | - | -$8.50 M(+90.9%) | -$24.92 M(+5.3%) |
| Mar 2018 | - | -$4.45 M(-28.1%) | -$23.67 M(-9.4%) |
| Dec 2017 | -$26.13 M(+107.7%) | -$6.20 M(+7.3%) | -$26.13 M(+2.6%) |
| Sep 2017 | - | -$5.78 M(-20.3%) | -$25.48 M(+18.4%) |
| Jun 2017 | - | -$7.25 M(+4.9%) | -$21.52 M(+28.4%) |
| Mar 2017 | - | -$6.91 M(+24.6%) | -$16.75 M(+33.2%) |
| Dec 2016 | -$12.58 M(+12.4%) | -$5.54 M(+205.3%) | -$12.58 M(+25.9%) |
| Sep 2016 | - | -$1.82 M(-26.9%) | -$9.99 M(-11.6%) |
| Jun 2016 | - | -$2.48 M(-9.2%) | -$11.30 M(-0.1%) |
| Mar 2016 | - | -$2.73 M(-7.5%) | -$11.31 M(+1.1%) |
| Dec 2015 | -$11.19 M(+62.9%) | -$2.96 M(-5.5%) | -$11.19 M(+6.7%) |
| Sep 2015 | - | -$3.13 M(+25.6%) | -$10.49 M(+16.6%) |
| Jun 2015 | - | -$2.49 M(-4.7%) | -$8.99 M(-3.4%) |
| Mar 2015 | - | -$2.61 M(+15.8%) | -$9.31 M(+35.6%) |
| Dec 2014 | -$6.87 M(+3385.8%) | -$2.26 M(+38.2%) | -$6.87 M(+57.6%) |
| Sep 2014 | - | -$1.63 M(-41.9%) | -$4.36 M(+43.5%) |
| Jun 2014 | - | -$2.81 M(+1583.2%) | -$3.04 M(+965.8%) |
| Mar 2014 | - | -$167.00 K(-165.7%) | -$284.80 K(+44.5%) |
| Dec 2013 | -$197.00 K(-95.1%) | $254.30 K(-181.6%) | -$197.10 K(-56.3%) |
| Sep 2013 | - | -$311.70 K(+416.1%) | -$451.40 K(+223.1%) |
| Jun 2013 | - | -$60.40 K(-23.8%) | -$139.70 K(+76.2%) |
| Mar 2013 | - | -$79.30 K | -$79.30 K |
| Dec 2012 | -$4.03 M | - | - |
FAQ
- What is Viridian Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Viridian Therapeutics?
- What is Viridian Therapeutics annual EBIT year-on-year change?
- What is Viridian Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Viridian Therapeutics?
- What is Viridian Therapeutics quarterly EBIT year-on-year change?
- What is Viridian Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Viridian Therapeutics?
- What is Viridian Therapeutics TTM EBIT year-on-year change?
What is Viridian Therapeutics annual earnings before interest & taxes?
The current annual EBIT of VRDN is -$235.89 M
What is the all time high annual EBIT for Viridian Therapeutics?
Viridian Therapeutics all-time high annual earnings before interest & taxes is -$197.00 K
What is Viridian Therapeutics annual EBIT year-on-year change?
Over the past year, VRDN annual earnings before interest & taxes has changed by -$106.50 M (-82.31%)
What is Viridian Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of VRDN is -$75.69 M
What is the all time high quarterly EBIT for Viridian Therapeutics?
Viridian Therapeutics all-time high quarterly earnings before interest & taxes is $254.30 K
What is Viridian Therapeutics quarterly EBIT year-on-year change?
Over the past year, VRDN quarterly earnings before interest & taxes has changed by -$28.63 M (-60.83%)
What is Viridian Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of VRDN is -$253.98 M
What is the all time high TTM EBIT for Viridian Therapeutics?
Viridian Therapeutics all-time high TTM earnings before interest & taxes is -$79.30 K
What is Viridian Therapeutics TTM EBIT year-on-year change?
Over the past year, VRDN TTM earnings before interest & taxes has changed by -$38.42 M (-17.82%)